R&D efforts on the part of major biopharmaceutical companies for novel drugs to treat depression and other CNS diseases have eroded over the past decade. In fact, a study published […]
Featured Posts
Abbott’s diabetes awareness campaign drives dialogue about patient access and affordable technology - The company’s new campaign, “Countdown at a Crossroads” featuring TV host Sherri Shepherd, shines a spotlight on how CGM technology can help people living with diabetes improve health outcomes and have a better quality of life. 
Top pharma companies 2023: A satisfactory year - As the COVID-19 pandemic continues to recede, the top pharma companies intensified their focus into areas such as cancer and metabolic diseases to build up their pipelines, and their growth prospects, for the future.Designed to prevent users from overdosing, abuse-deterrent opioids aim to diminish the effects of today’s epidemic by limiting the ways addicts can alter prescription painkillers for their needs. These drugs, subject […]
SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the FDA has approved a supplemental New Drug Application (sNDA) for the use of Promacta® (eltrombopag), a Novartis product, for the […]
Seven times between August 11, 2008, and June 27, 2013, the Food and Drug Administration declined to approve a new medicine, in part, because patients were more likely to die […]
That’s a pretty provocative headline coming from an Avalere report sponsored by America’s Health Insurance Plans (AHIP), the national trade association that represents the health insurance industry. At a time […]
Januvia, a widely used diabetes drug that generates $6 billion in annual sales for maker Merck, does not increase patients’ risk of being hospitalized for heart failure, a risk that […]
The U.S. biotechnology arena is undergoing a record-breaking M&A cycle for the industry. After generating M&A activity valued at $235 billion during 2014, the U.S. biotech sector produced more than $100 billion in deals during first-quarter 2015.
While development of personalized medicines has grown since the human genome was first sequenced in 2001, biopharmaceutical sponsors face a number of hurdles that are impeding more rapid market uptake, […]
How to determine the right strategy for mature brands By Tim Arendt, Fahti Khosrow-Shahi, and Seb Morisot Tim Arendt is VP, Fahti Khosrow-Shahi is managing director, and Seb Morisot is […]
The growth of communities such as Inspire and PatientsLikeMe, coupled with FDA’s recent guidance on social media in pharma, point to how patients will increasingly merit pharma’s attention. When the […]
